Brief: Veracyte Q2 Revenue USD 114.4 Million Vs. IBES Estimate USD 100.3 Million
06/08/2024 21:05
Aug 06 (Reuters) - Veracyte Q2 gross margin 68%. * Q2 net income USD 5.7 million * outlook FY revenue growth 20-21% * outlook FY revenue USD 432-438 million
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina